RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Making Sense of FDA’s Postmarket Surveillance Program

Making Sense of FDA’s Postmarket Surveillance Program

Posted 01 September 2009

Throughout the clinical development process, sponsors maintain a laser-like focus on getting to the finish line-receiving marketing approval from the US Food and Drug Administration (FDA) for a drug, biologic or medical device. But what happens next, when the product is launched and is now available to the public? That is when sponsors realize that the game really is only half over, and postmarket surveillance comes into play to monitor the newly approved product throughout its lifecycle.

 

© 2022 Regulatory Affairs Professionals Society.